NASDAQ · BIVI
Healthcare · Biotechnology
$1.86
Up+$0.09 (+4.84%)
Updated Aug 21, 2026, 10:34 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BIVI closed at $1.86 after 21 trading sessions, up 29.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $1.545 | $2.39 | $1.4901 | $1.86 | 49.11M |
| Aug 19, 2026 | $1.30 | $1.44 | $1.14 | $1.34 | 42.47M |
| Aug 18, 2026 | $1.13 | $1.14 | $0.945 | $0.9644 | 10.54M |
| Aug 17, 2026 | $1.32 | $1.56 | $1.17 | $1.17 | 2.76M |
| Aug 14, 2026 | $1.415 | $1.515 | $1.245 | $1.40 | 2.12M |
| Aug 13, 2026 | $1.65 | $1.70 | $1.48 | $1.56 | 4.88M |
| Aug 12, 2026 | $1.35 | $3.79 | $1.31 | $1.56 | 126.4M |
| Aug 11, 2026 | $1.09 | $1.415 | $1.09 | $1.27 | 2.71M |
| Aug 10, 2026 | $0.9896 | $1.155 | $0.9852 | $1.10 | 1.25M |
| Aug 7, 2026 | $1.22 | $1.23 | $0.98 | $0.9993 | 3.46M |
| Aug 6, 2026 | $1.36 | $1.41 | $0.82 | $1.35 | 8.78M |
| Aug 5, 2026 | $1.89 | $2.09 | $1.87 | $2.04 | 247.94K |
| Aug 4, 2026 | $1.63 | $1.90 | $1.535 | $1.83 | 397.68K |
| Aug 3, 2026 | $1.50 | $1.65 | $1.46 | $1.62 | 119.44K |
| Jul 31, 2026 | $1.45 | $1.55 | $1.38 | $1.52 | 203.81K |
| Jul 30, 2026 | $1.30 | $1.45 | $1.30 | $1.43 | 225.46K |
| Jul 29, 2026 | $1.34 | $1.3994 | $1.26 | $1.26 | 81.59K |
| Jul 28, 2026 | $1.36 | $1.4014 | $1.31 | $1.33 | 106.21K |
| Jul 27, 2026 | $1.36 | $1.43 | $1.35 | $1.37 | 75.56K |
| Jul 24, 2026 | $1.45 | $1.49 | $1.34 | $1.37 | 112.04K |
| Jul 23, 2026 | $1.34 | $1.46 | $1.34 | $1.44 | 85.47K |
The latest Smart Investors Daily articles mentioning BIVI.
BIVI research
Company profile and research snapshot.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2024 | ThinkEquity | Buy | — |
| Nov 30, 2023 | Oppenheimer | Outperform | — |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Jul 18, 2023 | Cantor Fitzgerald | Overweight | — |
| May 17, 2023 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular session. The company's market cap stands at $4.4 million. Tenon Medical (NASDAQ:TNON) shares moved upwards by
Benzinga · Aug 13, 2026
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.70) per share. This is a 50.7 percent increase over losses of $(1.42) per share from the same period last year.
SeekingAlpha · Aug 12, 2026
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design August 12, 2026 4:15 PM EDTCompany ParticipantsCuong Viet...
Benzinga · Jun 18, 2026
-SEC Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BIVI.
